PD ‐ L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC ‐ RPE Grafts in Retinal Degeneration
Cell Proliferation · 2025
DOI: 10.1111/cpr.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Bowen Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), Chongqing, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Retinal Pigment Epithelium, Human Embryonic Stem Cells, Immune Tolerance. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Immune rejection is a major barrier to the successful human embryonic stem cell‐derived retinal pigment epithelial (hESC‐RPE) transplantation for age‐related macular degeneration (AMD). Traditional strategies to mitigate immune rejection involve ablating major histocompatibility complex (MHC) molecules on hESC‐RPE. An alternative approach is immune checkpoint overexpression, avoiding natural killer (NK) cell‐mediated destruction due to MHC‐I deficiency. Our study highlights the benefits of PD‐L1 overexpression without requiring MHC gene deletion, which preserved the immunosuppressive functions of hESC‐RPE on NK cells. In Vivo experiments in retinal degeneration models showed that PD‐L1‐expressing hESC‐RPE grafts exhibited significantly higher survival, reduced apoptosis and enhanced visual protection. Single‐cell transcriptomics revealed reduced immune activation and oxidative stress in PD‐L1‐overexpressing grafts. PD‐L1's protective role was further evidenced by improved light transduction in host photoreceptors. These findings support PD‐L1 overexpression as a promising strategy to improve the efficiency of hESC‐RPE‐based therapy for AMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing, China.
- Jinfeng Laboratory, Chongqing, China.
ORCID-Profile: Yong Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Li, B., Zhang, X., Fang, Y., Chen, M., Li, Q., Zeng, Y., Ren, C., Wang, C., Lv, Y., Lu, J., Liu, H., & Liu, Y. (2025). PD ‐ L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC ‐ RPE Grafts in Retinal Degeneration. Cell Proliferation. https://doi.org/10.1111/cpr.70007
Vancouver
Li B, Zhang X, Fang Y, Chen M, Li Q, Zeng Y, et al. PD ‐ L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC ‐ RPE Grafts in Retinal Degeneration. Cell Proliferation. 2025. doi:10.1111/cpr.70007
BibTeX
@article{Li2025,
author = {Li, Bowen and Zhang, Xue and Fang, Yajie and Chen, Min and Li, Qiyou and Zeng, Yuxiao and Ren, Chunge and Wang, Chengang and Lv, Yingxue and Lu, Jia and Liu, Hongling and Liu, Yong},
title = {PD ‐ L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC ‐ RPE Grafts in Retinal Degeneration},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.70007}
}
EUVIMED